Introduction {#S0001}
============

Osteoporosis is a common complex genetic disease in postmenopausal women, characterized by decreased bone mineral density (BMD), increased bone fragility and fracture risk. It is a major public health issue \[[@CIT0001]\]. The World Health Organization estimates that 200 million women and men suffer from osteoporosis worldwide \[[@CIT0002]\]. In the United States and the European Union, approximately 30% of all postmenopausal women have osteoporosis, and it has been predicted that more than 40% of them will suffer one or more fragility fractures during their remaining lifetime \[[@CIT0003]\]. Many environmental factors have been identified as risk factors of osteoporosis, including exercise and calcium intake \[[@CIT0004]\]. In addition, twin and family studies have shown that approximately 50--85% of heritability for BMD in the general population may be attributed to genetic factors \[[@CIT0005]\]. Genetic factors may also play a role in the development of osteoporosis \[[@CIT0006]\].

Vitamin D plays a crucial role in calcium and phosphate homeostasis and skeletal metabolism. Furthermore, the vitamin D receptor (VDR) plays an important role in cellular differentiation and the control of proliferation in a variety of cell types. The VDR gene located on the long arm of chromosome 12 (12q13.11) is a member of the nuclear receptor superfamily, and many studies have shown that VDR gene polymorphisms play an important role in the pathogenesis of osteoporosis \[[@CIT0007]\]. VDR polymorphisms include VDR TaqI (rs17880019), VDR BsmI (rs1544410), VDR FokI (rs17881966), and VDR ApaI (rs17879735) \[[@CIT0008], [@CIT0009]\].

BsmI gene polymorphism is an important subtype of VDR gene polymorphisms, with genotypes BB, Bb, or bb by polymerase chain reactions based on polymorphism at the BsmI restriction site. Since 1996 when Berg *et al*. first reported that VDR BsmI polymorphism could affect osteoporosis in postmenopausal women \[[@CIT0010]\], to date, a great number of studies regarding the association between BsmI gene polymorphism and osteoporosis in postmenopausal women have been published. However, the results remain controversial. The aim of this study was to investigate the association between BsmI gene polymorphism and osteoporosis risk in postmenopausal women by conducting a meta-analysis from all eligible case-control studies published.

Material and methods {#S0002}
====================

Search strategy {#S20003}
---------------

The study retrieval was conducted using PubMed, EMBASE and the China National Knowledge Infrastructure (CNKI) databases with the following keywords: "BsmI polymorphism", "vitamin D receptor", and "osteoporosis" dating up until July of 2013. The references of the eligible articles or textbooks were also reviewed to check through manual searches to find other potential studies. When pertinent data were not included, or data that were presented were unclear, the authors were contacted directly. Any disagreement was resolved by discussion between the authors.

Selection criteria {#S20004}
------------------

The resulting reports were filtered using the following inclusion criteria: (i) case-control studies that addressed osteoporosis cases and healthy controls; (ii) studies on the association of VDR BsmI polymorphism and susceptibility to osteoporosis; (iii) studies that included sufficient genotype data for extraction. The following studies were excluded: (i) not case-control studies that evaluated the association between VDR BsmI polymorphism and osteoporosis risk; (ii) case reports, letters, reviews, and editorial articles; (iii) reports in which the number of null and wild genotypes could not be ascertained.

Data extraction {#S20005}
---------------

Two investigators (Bizeng Zhao and Wei Zhang) independently extracted the data with a standard protocol and the results were reviewed by a third investigator (Zubin Zhou). Discrepancies were resolved by discussion with our research team. For each study, the following characteristics were collected: the first author, year of publication, country of the study and ethnicity, genotype method, allele and genotype frequencies, and evidence of Hardy-Weinberg equilibrium (HWE) in controls. Different ethnic descents were categorized as European and Asian that included subjects of more than one ethnicity.

Statistical analysis {#S20006}
--------------------

We calculated the odds ratio (OR) and corresponding 95% confidence interval (CI) to evaluate the association between the VDR BsmI polymorphism and osteoporosis risk under a homozygote comparison (BB vs. bb), a heterozygote comparison (BB vs. Bb), a dominant model (bb + Bb vs. BB) and a recessive mode (BB + Bb vs. bb) between groups. We quantified the effect of heterogeneity by using the *I*^2^ test, which ranges from 0 to 100% and represents the proportion of inter-study variability that can be contributed to heterogeneity rather than chance \[[@CIT0011], [@CIT0012]\]. When *I*^2^ \> 50% indicated heterogeneity across studies, the random effects model was used for meta-analysis, or else the fixed effects model was used. Subgroup analysis was performed according to ethnicity. The different ethnicities were categorized as Asians and Europeans. To test for robustness of the summary effects, sensitivity analysis was performed by comparison of random effect model values to the fixed effect to ensure the stability of the findings. All analyses were conducted using Stata 12.0 (Stata-Corp LP, College Station, TX, USA).

Results {#S0007}
=======

Studies and data included {#S20008}
-------------------------

According to the inclusion criteria, 10 studies were included \[[@CIT0010], [@CIT0013]--[@CIT0020]\]. The flow chart of the study selection is shown in [Figure 1](#F0001){ref-type="fig"}. The total osteoporosis cases and healthy controls numbered 1403 and 2144 respectively, in the 10 case-control studies that evaluated the relationship between BsmI polymorphism and the risk of osteoporosis. The publication year of the involved studies ranged from 1996 to 2009. Of the 10 included studies, 9 used the restriction fragment length polymorphism (PCR-RFLP) method and one used the TKM method \[[@CIT0018]\]. Meta-analysis of the relationship between VDR gene BsmI polymorphism and osteoporosis risk using BB vs. bb model ([Figure 2](#F0002){ref-type="fig"}). The HWE test was performed on the genotype distribution of the controls in all included studies. All of them were in HWE except those of Douroudis *et al*., Zhu *et al*. and Ge *et al*. The main characteristics of included studies are listed in [Table I](#T0001){ref-type="table"}. Of these studies, 7 reported on Europeans, and 3 reported on Asians.

![Flow chart showing study selection procedure](AMS-12-26824-g001){#F0001}

![Meta-analysis of the relationship between VDR gene BsmI polymorphism and osteoporosis risk using BB vs. bb model](AMS-12-26824-g002){#F0002}

###### 

Characteristics of studies included in the meta-analysis

  First author     Year   Country   Ethnicity   Genotyping method   Genotypes for cases   Genotypes for controls   HWE test                     
  ---------------- ------ --------- ----------- ------------------- --------------------- ------------------------ ---------- ----- ----- ----- ------
  Berg             1996   Norway    European    RFLP                4                     8                        7          8     11    11    0.16
  Vandevyver       1997   Belgium   European    RFLP                12                    50                       24         127   368   203   0.08
  Gomez            1999   Spain     European    RFLP                13                    38                       25         38    109   89    0.63
  Valimaki         2001   Finland   European    RFLP                44                    175                      153        20    55    36    0.90
  Douroudis        2003   Greece    European    RFLP                3                     12                       20         10    29    5     0.03
  Garnero          2005   France    European    RFLP                50                    124                      66         40    162   147   0.64
  Horst-Sikorska   2007   Poland    European    RFLP                10                    35                       40         33    85    73    0.34
  Zhu              2004   China     Asian       RFLP                6                     26                       8          7     105   46    0.00
  Mitra            2006   India     Asian       TKM method          19                    38                       40         51    46    22    0.05
  Ge               2009   China     Asian       RFLP                6                     33                       314        4     12    192   0.00

RFLP -- Restriction fragment length polymorphism.

Results of meta-analysis {#S20009}
------------------------

A summary of the meta-analysis findings of the association between VDR BsmI polymorphism and osteoporosis risk is shown in [Table II](#T0002){ref-type="table"}. Meta-analysis results showed that there was no association between BsmI polymorphism and the risk of osteoporosis (BB vs. bb: OR = 0.76, 95% CI: 0.39--1.48; BB vs. Bb: OR = 0.90, 95% CI; 0.71--1.15; dominant model: OR = 1.20, 95% CI: 0.74--1.93; recessive model: OR = 0.83, 95% CI: 0.53--1.30). In the subgroup analysis based on ethnicity, the included studies were divided into Asian and European populations, and the results also showed no significant association between BsmI polymorphism and susceptibility to osteoporosis in both Asian and European populations. Sensitivity analysis was performed by comparing random effect model values to the fixed effect, and the significance of pooled OR in all individual analyses and subgroup analyses was not influenced.

###### 

Summary ORs and 95%CI of BsmI gene polymorphism with bone mineral density risk

  Subgroup          Genetic model   Sample size   Type of model   Test of heterogeneity   Test of association   Sensitivity analysis                                          
  ----------------- --------------- ------------- --------------- ----------------------- --------------------- ---------------------- ------------ ------------ ------------ ------------
  Overall           BB vs. bb       1403          2144            Random                  83.6                  \< 0.001               0.76         0.39--1.48   0.87         0.68--1.11
  BB vs. Bb                                       Fixed           42.8                    0.06                  0.90                   0.71--1.15   0.88         0.61--1.26   
  Dominant model                                  Random          71                      \< 0.001              1.20                   0.74--1.93   1.15         0.92--1.43   
  Recessive model                                 Random          81.4                    \< 0.001              0.83                   0.53--1.30   0.97         0.82--1.15   
  European          BB vs. bb       978           1692            Random                  78.3                  \< 0.001               0.74         0.36--1.51   1.01         0.76--1.32
  BB vs. Bb                                       Fixed           8.3                     0.37                  0.96                   0.74--1.26   0.93         0.68--1.28   
  Dominant model                                  Random          59.8                    0.02                  1.14                   0.75--1.74   1.01         0.80--1.29   
  Recessive model                                 Random          81.5                    \< 0.001              0.77                   0.48--1.26   0.98         0.81--1.18   
  Asian             BB vs. bb       490           485             Random                  88.8                  \< 0.001               0.92         0.14--6.14   0.51         0.30--1.07
  BB vs. Bb                                       Random          77.5                    0.01                  0.92                   0.25--3.38   0.70         0.41--1.19   
  Dominant model                                  Random          85.8                    \< 0.001              1.03                   0.22--4.73   1.73         1.07--2.82   
  Recessive model                                 Random          86.8                    \< 0.001              0.91                   0.31--2.68   0.85         0.60--1.21   

Publication bias {#S20010}
----------------

The publication bias of the meta-analysis of the association between VDR BsmI polymorphism and osteoporosis risk was detected by Begg\'s funnel plot. All graphical funnel plots of the included studies appeared to be symmetrical. There was no visual evidence of publication bias visually from the funnel plot, which implied that the publication bias was low in the present overall meta-analysis (BB vs. bb: *p* = 0.806; BB vs. Bb: *p* = 0.806; dominant model: *p* = 0.806; recessive model: *p* = 0.806).

Discussion {#S0011}
==========

Osteoporosis is a multifactorial disorder with a strong genetic component, and the VDR gene has been suggested as a candidate gene for osteoporosis \[[@CIT0021]\]. The VDR gene has been widely studied due to its crucial role in the regulation of bone turnover and homeostasis. Active vitamin D as the ligand of VDR plays an important role in intestinal and renal calcium absorption, as well as subsequent, normal bone mineralization and remodeling \[[@CIT0022]\]. VDR BsmI gene polymorphism is one of the most important subtypes of VDR gene polymorphisms. To date, a variety of studies has been conducted to identify whether the VDR BsmI polymorphism was the genetic determiner of osteoporosis. However, conflicting results have been obtained. Zintzaras *et al*. performed a meta-analysis to study the relationship between VDR gene polymorphism and the risk of osteoporosis, and found that there was no evidence of a relationship between BsmI polymorphism and osteoporosis risk \[[@CIT0023]\]. Post-menopausal women were regarded as a 'high-risk' population for low osteoporosis; therefore, we conducted a meta-analysis to evaluate the relationship between VDR BsmI gene polymorphism and susceptibility to osteoporosis. Our meta-analysis is the first to examine this relationship of VDR BsmI gene polymorphism with osteoporosis risk in post-menopausal women. Overall, the results showed that the VDR BsmI polymorphism may not be an osteoporosis susceptibility gene in post-menopausal women. Considering that the result may be affected by ethnicity, we performed a race-related subgroup analysis, and again no significant association was found between BsmI polymorphism and susceptibility to osteoporotic fracture in post-menopausal women in both Caucasian and Asian populations. Sensitivity analysis was performed by comparing random effect model values to the fixed effect, and the result revealed that this meta-analysis was realistic and believable. There was no evidence of publication bias in this meta-analysis (all *p* \> 0.05). As the eligible study number was small in this meta-analysis, these results still need further investigation.

The potential function of BsmI polymorphism might be affected by gene-gene and gene-environment interactions. A previous study demonstrated that polymorphisms of both genes (BsmI polymorphism and estrogen receptor genotypes) increased osteoporosis risk and found that BsmI polymorphism alone did not increase the osteoporosis risk \[[@CIT0008], [@CIT0024]\]. In addition, obesity can mask the effects of the VDR genotypes on BMD as reported by Dawson-Hughes \[[@CIT0025], [@CIT0026]\]. As one study could not be included in our meta-analysis, further studies of gene-gene and gene-environment interactions should be taken into consideration.

The present study has some limitations. First, the number of studies included in the systematic review might have been too small to detect slight associations within ethnic groups. Second, heterogeneity exists between studies, possibly owing to covariates: age and years from onset, gender, fraction of patients among these studies, and so on.

In conclusion, our meta-analysis suggests no association between BsmI polymorphism and osteoporosis risk, both in Caucasian and Asian populations. Large-scale case-control and population-based association studies are warranted to validate the risk identified in the current meta-analysis.
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